ABSTRACT
Objective: To explore the induction chemotherapy and consolidation therapy for primary central nervous system lymphoma (PCNSL), and in order to improve the clinical understanding of this type of lymphoma, and to provide experiences in systemic therapy. Methods: A case of diffuse large B-cell PCNSL was reported. The clinical features, diagnosis and the treatment were reviewed, and the relevant literatures were reviewed and discussed. Results: The patient with diffuse large B-cell PCNSL was treated with high-dose methotrexate-based induction chemotherapy, then sequentially received two courses of high-dose chemotherapy (HDC) with thiotepa/autologous stem cell transplant (ASCT), and achieved significant clinical efficacy with sustained remission after transplantation. Conclusion: PCNSLis a group of uncommon primary brain tumors. Thiotepa-based HDC/ASCT as consolidation therapy may play an important role in improvement of prognosis, especially for young patients.
ABSTRACT
The sterile insect technique (SIT) is a promising pest control method in terms of efficacy and environmental compatibility. In this study, we determined the efficacy of thiotepa-sterilised males in reducing the target Aedes aegypti populations. Treated male pupae were released weekly into large laboratory cages at a constant ratio of either 5:1 or 2:1 sterile-to-fertile males. A two-to-one release ratio reduced the hatch rate of eggs laid in the cage by approximately a third and reduced the adult catch rate by approximately a quarter, but a 5:1 release drove the population to elimination after 15 weeks of release. These results indicate that thiotepa exposure is an effective means of sterilising Ae. aegypti and males thus treated are able to reduce the reproductive capacity of a stable population under laboratory conditions. Further testing of the method in semi-field enclosures is required to evaluate the mating competitiveness of sterile males when exposed to natural environmental conditions. If proven effective, SIT using thiotepa-sterilised males may be incorporated into an integrated programme of vector control to combat dengue in Cuba.
Subject(s)
Animals , Female , Male , Aedes/drug effects , Mosquito Control/methods , Thiotepa/pharmacology , Dengue/prevention & controlABSTRACT
Objective: Patients with high-risk breast cancer has a high recurrence rate. The clinical value of high-dose adjuvant chemotherapy supported by autologous HSCT (hematopoietic stem cell transplantation) for postoperative breast cancer patients with high risk of recurrence remains controversial. This study was to explore the efficacy and safety of high-dose adjuvant chemotherapy with paxlitaxel and thiotepa supported by autologous HSCT for postoperative breast cancer patients with high risk of recurrence. Methods: Twenty-four postoperative breast cancer patients (stages II-III) with high risk of recurrence were enrolled in this study. The patients received paclitaxel 175 mg/m2 and G-CSF (granulocyte colony-stimulating factor) 5 μg/kg for mobilization and collection of peripheral blood CD34+ stem cells. Then two cycles of high-dose adjuvant chemotherapy were given subsequently [11 patients: paclitaxel 175 mg/m2 + thiotepa 150 mg/m2 + carboplatin (area under curve = 6; 300 mg/m2 divided in two days); 13 patients: paclitaxel 175 mg/m2 + thiotepa 150 mg/m2) every 28 d]. The CD34+ stem cells were infused for an autologous HSCT on day 2 after chemotherapy, and the G-CSF was started on day 3 after chemotherapy and discontinued until the peripheral WBC (white blood cell) count reached over 10.0×109/L continuously for three days. The adverse effects of high-dose adjuvant chemotherapy were observed. The median DFS (disease-free survival) and the three-year DFS rate were calculated. Results: The median follow-up was 32 months (3-62 months). The median DFS was 32 months. The three-year DFS rate was 56.3%. High-dose chemotherapy had a good safety profile and no treatment-related death. Conclusion: High-dose chemotherapy with paclitaxel and thiotepa supported by autologous HSCT in postoperative breast cancer patients with high risk of recurrence has a good safety profile and can obtain a better benefit of DFS as compared with standard-dose chemotherapy. These results suggest that this treatment strategy deserves further exploration. Copyright © 2013 by TUMOR.
ABSTRACT
Los tumores vesicales superficiales se caracterizan por una alta tasa de recidiva, que ocurre especialmente dentro de los dos primeros años, y que es aun mayor en los grupos de alto riesgo. Existe consenso en la utilidad del uso del Bacilo de Calmette-Guerin para disminuir la recurrencia tumoral. La quimioterapia intravesical con otros medicamentos han demostrado su utilidad o no en disminuir la recurrencia de estos tumores vesicales. Entre los años 1999 y 2008 se estudian y tratan 110 pacientes (96 hombres y 14 mujeres), con una edad promedio de 63 años, divididos en tres grupos para tratamiento de la recidiva tumoral después de resección transuretral o cistectomía parcial, con tres diferentes agentes quimioprofilácticos e inmunomoduladores (Thio-Tepa, BCG+factor de transferencia, doxorrubicina+interferón alfa 2b). El objetivo de esta investigación fue presentar la experiencia en el tratamiento de estos pacientes, donde se observa mejores resultados en 5 años, con el grupo tratado con doxorrubicina+interferón alfa 2b, seguido del grupo tratado con BCG+factor de transferencia, con una marcada disminución de las recurrencias y una limitación en la progresión de la enfermedad a largo plazo.
The superficial bladder tumors are characterized by a high rate of recurrence taking place especially within the first two years that is even higher in the high risk groups. There is an agreement in the usefulness of the Calmette-Guerin Bacillus (CGB) to diminish the tumoral recurrence. The intravesical chemotherapy with other medications have demonstrated its profit or not in decreasing the recurrence of these bladder tumors. Between 1999 and 2008 we studied and treated 110 patients (96 men and 14 women), aged in average 63 years old. They were divided into three groups for the treatment of the tumoral recidivism after the transurethral resection or partial cystectomy, using three different chemoprophylactic agents and inmunomodulators (Thio-Tepa, BCG+Transference Factor, Doxorubicin +Interferon Alpha 2b). The objective of this research was presenting our experience in the treatment of these patients during five years, obtaining better results in the group treated with doxorubicin + interferon alpha 2b, followed by the group treated by means of BCG + transference factor, with a remarked decrease of the recurrence and a limitation in the long term progression of the disease.
ABSTRACT
OBJECTIVE: To investigate whether the polymorphisms of cytochrome P450 3A5 (CYP3A5) gene and glutathione S-transferase P1 (GSTP1) gene are associated with the short-term efficacy of docetaxel plus thiotepa for Chinese patients with metastatic breast cancer. METHODS: All patients received docetaxel plus thiotepa chemotherapy. CYP3A5 and GSTP1 were genotyped by matrix assisted laser desorption ionization / time of flight (MALDI-TOF). Disease control rate (DCR) was evaluated every two chemotherapy cycles, and was compared between different genotypes. RESULTS: Among 93 enrolled patients, people with CYP3A5 A6986G GG genotype showed a statistically higher DCR than those with AG + GG genotype (77.8% versus 57.4%, P < 0.05), and the DCR of the patients with GSTP1 A313G AG + GG was statistically higher than that of patients with AA (81.6% versus 57.4%, P < 0.05). Combination analysis showed that patients with GSTP1 A313G AG + GG and CYP3A5 A6986G GG had the highest DCR (84.2%, P < 0.05). CONCLUSION: CYP3A5 and GSTP1 polymorphisms are associated with the short-term efficacy of docetaxel plus thiotepa. Higher DCRs were seen in patients carrying GSTP1 A313G AG + GG and / or CYP3A5 A6986G GG genotype, which might be a reference for clinical chemotherapy. Copyright 2012 by the Chinese Pharmaceutical Association.
ABSTRACT
Objective To evaluate the efficacy and feasibility of Flu/ivBu/Tl" conditioning regimen for the treatment of refractory or relapsed acute non-lymphocytic leukemia in patients receiving allogeneic hematopoietie stem cell transplantation. Methods Seven patients with refractory or relapsed acute non-lymphocytic leukemia received HLA identical peripheral blood hematopoietie stem cell transplantation (PBSCT) following Flu/ivBu/TY conditioning regimen, which consisted of fludarbine, busulfex and thiotepa. All patients received cyclos-porin A (CsA) and mycophenolet mofetil (MMF) for prophylaxis of graft - versus - host disease (GVHD). Results The Flu/IVBu/TT regimen was tolerated very well, without severe regimen related toxicity. In the 31-month median follow-up duration, 5 of 7 patients were a-live in disease-free situation. Conclusion The Flu/ivBu/TT conditioning regimen reduced transplantation-related toxicities and offered high long-term disease-free survival, and was tolerated very well. Allogeneie hematopoietie stem cell transplantation using Flu/ivBu/TT condition-ing regimen is a safe and effective option for the patients with refractory/relapsed acute non-lymphocytic leukemia.
ABSTRACT
PURPOSE: The benefit of consolidation high-dose chemotherapy (HDC) for high-risk primary breast cancer is controversial. We evaluated the efficacy and safety of consolidation HDC with cyclophosphamide, thiotepa and carboplatin (CTCb) followed by autologous stem-cell transplantation (ASCT) in resected breast cancer patients with 10 or more positive lymph nodes. MATERIALS AND METHODS: Between December 1994 and April 2000, 22 patients were enrolled. All patients received 2 to 6 cycles of adjuvant chemotherapy after surgery for breast cancer. The HDC regimen consisted of cyclophosphamide 1, 500 mg/m2/day, thiotepa 125 mg/m2/day and carboplatin 200 mg/m2/day intravenous for 4 consecutive days. RESULTS: With a median follow-up of 58 months, 11 patients recurred and died. The median disease-free survival (DFS) and median overall survival (OS) were 49 and 69 months, respectively. The 5-year DFS and OS rates were 50% and 58%, respectively. The 12 patients with 10 to 18 involved nodes had better 5-year DFS (67%) and OS (75%) than 10 patients with more than 18 involved nodes (30% and 38%, respectively). The most common grade 3 or 4 nonhematologic toxicity was diarrhea, which occurred in 5 patients (23%). No treatment-related death was observed. CONCLUSION: Consolidation HDC with CTCb followed by ASCT for resected breast cancer with more than 10 positive nodes had an acceptable toxicity but does not show promising survival.
Subject(s)
Humans , Breast Neoplasms , Breast , Carboplatin , Chemotherapy, Adjuvant , Cyclophosphamide , Diarrhea , Disease-Free Survival , Drug Therapy , Follow-Up Studies , Lymph Nodes , Peripheral Blood Stem Cell Transplantation , ThiotepaABSTRACT
PURPOSE: The benefit of high-dose chemotherapy (HDC) for metastatic breast cancer (MBC) is controversial. We evaluated the efficacy and safety of HDC with cyclophosphamide, thiotepa, and carboplatin (CTCb) followed by autologous stem-cell transplantation (ASCT) for MBC patients. MATERIALS AND METHODS: From September 1994 to December 1999, 23 MBC patients were enrolled. All the patients received 2 to 10 cycles of induction chemotherapy. Before transplantation, 12 patients were in complete response (CR), nine were in partial response (PR), and two had progressive disease (PD). The HDC regimen consisted of cyclophosphamide 1, 500 mg/m2/day, thiotepa 125 mg/m2/day and carboplatin 200 mg/m2/day intravenously for 4 consecutive days RESULTS: After ASCT, 13 patients (56%) had a CR, five (22%) had a PR, three (13%) had no change, while two (9%) showed a PD. Seventeen patients relapsed or progressed during the median follow-up of 78 months. The median progression-free survival (PFS) time was 11 months and the median overall survival (OS) time was 23 months. The 5-year PFS and OS rates were 22% and 25%, respectively. On the multivariate analyses, less than 4 involved lymph nodes was predictive of a better PFS and OS. CONCLUSION: HDC with CTCb for MBC has acceptable toxicity; however, this treatment does not show a survival benefit.
Subject(s)
Humans , Breast Neoplasms , Breast , Carboplatin , Cyclophosphamide , Disease-Free Survival , Drug Therapy , Follow-Up Studies , Induction Chemotherapy , Lymph Nodes , Multivariate Analysis , ThiotepaABSTRACT
BACKGROUND: The purpose of this study was to evaluate the toxicity and efficacy of high-dose chemotherapy with busulfan, thiotepa and melphalan (BTM) as a myeloablative regimen in allogeneic bone marrow transplantation (allo-BMT) for patients with acute myelogenous leukemia (AML). METHODS: Twenty-seven patients with AML were enrolled; Sixteen patients had standard risk (SR) diseases (first complete remission (CR1) and de novo AML) and eleven patients had high risk (HR) diseases (second, or subsequent remission, secondary AML, relapsed, or refractory AML, CR marrow with persisting extramedullary manifestation (chloroma), or hypoplastic acute leukemia). The conditioning regimen included busulfan 4 mg/kg/day for a total dose of 12 mg/kg; thiotepa 250 mg/m2/day for a total dose of 500 mg/m2; and melphalan 50 mg/m2/day for a total dose of 100 mg/m2. Cyclosporine A and short-course methotrexate were used for graft-versus-host disease (GVHD) prophylaxis. RESULTS: The median time to recovery a granulocyte count of 0.5 x 109/L was 14 days (range 10~25 days) and platelet transfusion independence was 30 days (range 12~49 days). The major regimen-related toxicities were gastrointestinal-related symptoms including oral mucositis, nausea, vomiting, and diarrhea. All patients experienced oral mucositis (> or = grade 1) and the patients with oral mucositis of equal and greater than grade 3 were 44% in SR and 45% in HR. The toxicities associated with lung, skin, heart and brain were minimal. Three (11%) patients had severe or fatal veno-occlusive disease (VOD). There were five treatment-related death (19%) (hepatic VOD with multiorgan failure (n=3), pneumonia and ARDS (n=2)) within the first 100 days after allo-BMT. There was not a significant difference between SR and HR group (p=0.167). The incidence of acute GVHD equal or greater than grade II was less than 10%. The actual survival at 2 year was 70.4%(95% confidence interval (CI), 54.7%~86.1%)(SR; 81.3% (95% CI; 63.4~99.1%) vs HR; 54.6% (95% CI; 28.7~80.4%), p=0.154). After a median follow-up of 630 days, 18 of 27 (67%, 355~1062 days) patients are alive without evidence of disease. Three of the 27 patients relapsed (SR; 0% vs HR; 55.6% (95% CI; 19.6~71.3%), p=0.004). CONCLUSION: The BTM regimen followed by allo-BMT is associated with acceptable toxicity and appears to have significant activity in patients with AML. It should be used with caution in patients with prior hepatopathy or refractory state who have an increased risk of severe VOD. Busulfan, thiotepa, and melphalan is an effective and alternative myeloablative regimen for patients with AML.
Subject(s)
Humans , Bone Marrow Transplantation , Bone Marrow , Brain , Busulfan , Cyclosporine , Diarrhea , Drug Therapy , Follow-Up Studies , Graft vs Host Disease , Granulocytes , Heart , Incidence , Leukemia, Myeloid, Acute , Lung , Melphalan , Methotrexate , Nausea , Platelet Transfusion , Pneumonia , Skin , Stomatitis , Thiotepa , Transplantation, Homologous , VomitingABSTRACT
Despite an aggressive surgical debulking followed by front-line chemotherapy, most patients with advanced ovarian carcinoma die of drug-resistant disease. Drug resistance can be overcome in a subset of patients with hematologic malignancies and lymphoma with high-dose therapy (HDT) and hematopoietic stem cell transplantation, suggesting that this therapy may also be value in ovarian carcinoma. We report the successful outcome of HDT and peripheral blood stem cell transplantation (PBSCT) in a 41-year-old nulliparous woman who initially was diagnosed with advanced ovarian carcicnoma with FIGO stage IIIc. Her disease relapsed after 19 months from initial therapy of definitive surgery and intra- and post-operative chemotherapy. Subsequently, she received optimal debulking surgery and salvage chemotherapy followed by HDT with triple- alkylating regimen, composed of cyclophosphamide (100 mg/kg), thiotepa (500 mg/m2), and melphalan (100 mg/m2). Her pretranplant characteristics were platinum-sensitive and complete response state. She showed rapid hematologic recovery and mild regimen-related toxicity (Bear man's toxicity criteria), stomatitis (grade I), cardiac toxicitiy (grade II). She has been followed up for 36 months after the inital therapy and is doing well without relapse.
Subject(s)
Adult , Female , Humans , Cyclophosphamide , Drug Resistance , Drug Therapy , Glycogen Storage Disease Type VI , Hematologic Neoplasms , Hematopoietic Stem Cell Transplantation , Lymphoma , Melphalan , Ovarian Neoplasms , Peripheral Blood Stem Cell Transplantation , Recurrence , Stomatitis , ThiotepaABSTRACT
Objective To probe the curative effect of thiotepa and mitomycin C for the prevention of the relapse of pterygium after its operation.Methods One hundred and eighty-two cases with pterygium were randomly divided into two groups:one group of thiotepa(158 cases with 169 eyes)and the other group of mitomycin C (24 cases with 24 eyes) and a comparative study was conducted.Thiotepa was used through dropping on the third day after the operation(1∶2 000),while MMC was used in the same way during the operation and on the third day after the operation respectively(0.2g*L-1).Results In the group of thiotepa,the wounded skin on the cornea was repaired significantly more rapidly than that in the group of mitomycin C,and the rate of the relapse of pterygium was lower in the former group than that in the latter one.Conclusion Applying thiotepa by dropping after the excision of pterygium is a safe,simple and effective supplementary measure for the prevention of pterygium relapse and also effective for recurring cases.
ABSTRACT
PURPOSE: We assessed the three-alkylator combination of busulfan, melphalan and thiotepa or TBI, melphalan and thiotepa conditioning for allogeneic stem cell transplantation in 7 adult patients with refractory or relapsed acute leukemias. MATERIALS AND METHODS: Six patients were transplanted for acute myeloid leukemia, one for acute lymphoblastic leukemia and included 5 of relapsed refractory, 2 of relapsed after first-BMT. All but 1 cases received G-CSF stimulated CD34+ allogeneic peripheral blood progenitor cells (PBPCs) in addition to stimulated allogeneic marrow. RESULTS: All patients except one engrafted (median time to ANC >0.5 10 (9)/L=11days, to platelets >30 X 10 (9)/L=14 days) successfully and complete remission was obtained in 6 patients. Grade I-II acute GVHD and controllable regimen-related toxicity especially oral mucositis (grade II-III) developed in all cases, but 2 patients including one second- allogeneic BMT patient expired early by transplant-related toxicity of hepatic or multiorgan failure along the course of sepsis. CONCLUSION: Although the observation period on these cases are limited, the data presented show that the combination of busulfan, melphalan and thiotepa is tolerable as a preparative regimen for allogeneic marrow transplantation in high-risk leukemic patients. We think that these encouraging results need to be confirmed in prospective studies in the future.
Subject(s)
Adult , Humans , Bone Marrow Transplantation , Bone Marrow , Busulfan , Drug Therapy , Granulocyte Colony-Stimulating Factor , Leukemia , Leukemia, Myeloid, Acute , Melphalan , Precursor Cell Lymphoblastic Leukemia-Lymphoma , Sepsis , Stem Cell Transplantation , Stem Cells , Stomatitis , ThiotepaABSTRACT
We compared the prophylactic efficacy of intravesical BCG with thiotepa instillation after complete removal of superficial bladder cancer. Forty patients received BCG and 32 received thiotepa. The mean followup period was 29 months in BCG group, and 34 months in thiotepa group. The overall recurrence rate was 35% in BCG group compared with 53% in thiotepa group, showing difference statistically(p0.05). The overall recurrence index per 100 patient-months was also lower for the BCG versus the thiotepa group(1.21 versus 1.56, p>0.05). One patient in the BCG group and 4 in the thiotepa group had recurrent tumors with progression in stage. Side effects were irritative voiding symptoms(100%), fever and chills(10%), and inguinal lymphadenitis(2.5%) in BCG group, while irritative voiding symptoms(25%), fever and chills(6.3%), and myelosuppression (6.3%) in thiotepa group. Our results suggest that BCG is significantly superior to thiotepa in reducing bladder tumor recurrence and in retarding tumor progression.
Subject(s)
Humans , Administration, Intravesical , Bacillus , Fever , Follow-Up Studies , Mycobacterium bovis , Recurrence , Thiotepa , Urinary Bladder Neoplasms , Urinary BladderABSTRACT
Mice were used to evaluate the adverse testicular effects of anticancer agents. Testicular cytotoxicity of many chemotherapeutic drugs has been evaluated in mice. In this report, we described thio-TEPA induced testicular toxicity in mature male I. C. R. mice. On day o, mice in the treatment groups were given different single intraperitoneal doses of thio-TEPA(0.1 to 25mg/kg). On day 56, all surviving mice were killed and necropsied. Testicular toxicity was evaluated qualitatively by histology and quantitatively by testicular weight(testis weight/body weight), repopulation index and epididymal index. Progressive dose dependent testicular atrophy and oligospermia occurred at low and intermediate doses of thio-TEPA(0.1 to 5mg/kg). Marked testicular atrophy, oligospermia and germinal aplasia were observed at high dose of thio-TEPA(10mg/kg). LD50 for animal mortality at day 56 for thio-TEPA appears to be 25mg/kg. In this report, we described the quantitative relationship between thio-TEPA dosage and testicular cytotoxicity in mature male I. C. R. mice.
Subject(s)
Animals , Humans , Male , Mice , Antineoplastic Agents , Atrophy , Lethal Dose 50 , Mortality , Oligospermia , Testis , ThiotepaABSTRACT
In a prospective study without crossover design, we were to compare the efficacy of Thiotepa and Mitomycin C when each was instilled intravesically after complete transurethral resection of all visible superficial bladder cancer(stage Ta, Tis and Tl) in 89 consecutive patients. The 3-months and 1year rates free of recurrence were 85.7 and 82.1 percent, respectively for Thiotepa(28 patients), 86.4 and 81.8 percent for Mitomycin C(22 patients), and 79.5 and 56.4 percent for control group(39 patients). Although Thiotepa intravesical instillation demonstrated effectiveness slightly superior to that of Mitomycin C, no significance difference in recurrence and progression rate was noted for either drug group. No patient required discontinuation of therapy in either group because of toxicity although 3 patients required temporary discontinuation of therapy secondary to myelosuppression (2) and symptomatic cystitis(1) in Thiotepa group, and 5 patients secondary to symptomatic cystitis(3) and rash or contact dermatitis(2) in mitomycin C group. This results suggest that Thiotepa is more useful and effective than Mitomycin C for the prophylactic treatment of superficial bladder tumor in cost saving, acceptable toxicity and patients`s convenience, in addition to decreasing the recurrence rate.
Subject(s)
Humans , Administration, Intravesical , Cost Savings , Cross-Over Studies , Drug Therapy , Exanthema , Mitomycin , Prospective Studies , Recurrence , Thiotepa , Urinary Bladder Neoplasms , Urinary BladderABSTRACT
Superficial bladder tumors are usually treated by TUR. However, recurrence of the tumor after complete resection occurs in about 50-70%, of the patients with a significant percentage of these recurrences showing a higher degree of malignancy. In 10% of the cases, the tumor progresses to invasive carcinoma. Most of these recurrent tumors will occur within 6-12 months. The multifocal nature of these tumors and the frequent recurrences after TUR indicate a need for adjuvant chemotherapy to reduce or delay the incidence of recurrence tumors. We studied to evaluate prophylactic effects of topical chemotherapy in 116 cases with superficial bladder tumors admitted to the Department of Urology, Keimyung University School of Medicine during the period from Jenuary, 1971 through July, 1985. All patients were followed up for more than 6 months. Study group consists of 83 cases (Thio-tepa: 39, Adriamycin; 44) treated with topical chemotherapy following TUR during the period from January, 1978 through July, 1985. Control group consists of 33 cases treated by TUR only during the period from January 1971 through December, 1977. Following results were obtained: 1. No. of patients with recurrence; In study group, 36Pr In control group. 67% 2. Average interval of recurrence: In study group, 38 months. In control group, 30 months 3. Recurrence rate; In study group, 2.58 In control group, 3.16 4. Complication: local side effects; In TUR + Thio-tepa, 20.5% In TUR + Adriamycin, 15.9%.
Subject(s)
Humans , Chemotherapy, Adjuvant , Doxorubicin , Drug Therapy , Incidence , Recurrence , Thiotepa , Urinary Bladder Neoplasms , Urinary Bladder , UrologyABSTRACT
20 cases of study group whose follow-up period is over 6 months among 22 cases of bladder tumors treated with doxorubicin instillation following TUR during the period from December, 1981 through December, 1983 were compared with 30 cases of controlled group whose follow-up period is over 6 months among 32 cases of bladder tumors treated with thio-tepa instillation following TUR during the period from January, 1978 through June, 1981. Following result were obtained. 1. Recurrence rate In TUR + doxorubicin, 25%, In TUR+thio-tepa,30% 2. Interval between TUR & the first recurrence: In TUR + doxorubicin, average 9 months, In TUR + thio-tepa, average 8.1 months 3. Complication: In TUR + doxorubicin, painful urination in 2 cases(10%), In TUR + thio-tepa, hematuria, dysuria, painful urination, and urethral stricture in 8 cases(26.7%).
Subject(s)
Doxorubicin , Dysuria , Follow-Up Studies , Hematuria , Recurrence , Thiotepa , Urethral Stricture , Urinary Bladder Neoplasms , Urinary Bladder , UrinationABSTRACT
Intravesical thio-tepa instillations for 25 patients with superficial bladder tumors were evaluated postoperatively to reconfirm its usefulness as a prophylactic agent. The over-all recurrence rate to prophylactic thio-tepa was 28%, with minor toxicity observed in 32% of the Cases. Thio-tepa Can be given safely in the postoperative period and is effective in decreasing the recurrence rate and prolonging interval free of disease of superficial bladder tumors.
Subject(s)
Humans , Postoperative Period , Recurrence , Thiotepa , Urinary Bladder Neoplasms , Urinary BladderABSTRACT
Intravesical thio-tepa instillations for 25 patients with superficial bladder tumors were evaluated postoperatively to reconfirm its usefulness as a prophylactic agent. The over-all recurrence rate to prophylactic thio-tepa was 28%, with minor toxicity observed in 32% of the Cases. Thio-tepa Can be given safely in the postoperative period and is effective in decreasing the recurrence rate and prolonging interval free of disease of superficial bladder tumors.
Subject(s)
Humans , Postoperative Period , Recurrence , Thiotepa , Urinary Bladder Neoplasms , Urinary BladderABSTRACT
Condyloma acuminatum is a common lesion of the penis and genitalia. It uncommonly involves the urethra but when it does the lesions are difficult to eradicate. Treatment has included excision, fiuguration, podophyline and thiotepa0 none of which has been entirely successful. We report a case of intraurethral condyloma acuminatum treated with thiotepa instillation in 27 years old male patient